Pricing Log in Create free account

Structure Therapeutics Inc. Sponsored ADR (GPCR) vs Ultragenyx Pharmaceutical Inc. (RARE)

Structure Therapeutics Inc. Sponsored ADR and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Structure Therapeutics Inc. Sponsored ADR and Ultragenyx Pharmaceutical Inc. are of similar size ($1.6B and $1.5B). Structure Therapeutics Inc. Sponsored ADR has the higher net margin (0.00% vs −81.7%) and the lower return on invested capital (−1,371.8% vs 0.00%). Across the 12 metrics below, Structure Therapeutics Inc. Sponsored ADR leads on 7 and Ultragenyx Pharmaceutical Inc. on 5.

Valuation

Metric GPCR RARE Biotechnology median
P/E n/m n/m 8.50
P/S n/m 2.07 9.71
P/B 1.12 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 1.66 9.21
Earnings yield (14.35%) (40.17%) (33.15%)
Free cash flow yield (14.75%) (33.34%) (25.50%)

Profitability

Metric GPCR RARE Biotechnology median
Gross margin 0.00% 83.12% 65.16%
Operating margin 0.00% (73.64%) 0.00%
Net margin 0.00% (81.73%) 0.00%
Free cash flow margin 0.00% (68.90%) 0.00%
Return on equity (20.21%) 838.86% (56.36%)
Return on assets (19.17%) (45.60%) (48.04%)
Return on invested capital (1,371.78%) 0.00% 0.00%

Growth

Metric GPCR RARE Biotechnology median
Revenue growth (TTM) — 17.51% 6.02%
EPS growth (last fiscal year) (2.47%) 7.31% 30.26%
Revenue growth, 5-year CAGR — 19.95% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GPCR RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 20.75 1.73 4.72
Net debt to EBITDA 8.27 1.35 0.96

Dividend

Metric GPCR RARE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GPCR RARE Biotechnology median
Market cap 1.58b 1.50b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack